Lenskart's IPO has turned valuation into a hot topic, splitting investors on whether to subscribe, wait for listing, or avoid altogether. The chatter centers on a roughly 70k crore market cap at the offer price, a figure many say is hard to justify for an eyewear retailer [2]. Critics argue the growth story doesn’t obviously warrant a tech-style premium, given the sector’s competitive, low-margin realities [3].
Valuation under the lens: 'Valuation defies logic' is a frequent refrain. Paying double- or triple-digit revenue multiples for a retailer with single-digit margins is more optimistic than grounded [3]. Some compare this to Paytm-style exuberance, or contrast with Zomato’s multiples, arguing the two aren’t apples to apples but the risk remains loud [3].
Mutual funds' discipline under fire: The debate questions how fund managers can back such lofty valuations without diluting discipline, especially when hype around IPOs runs high [3]. The fear is mutual funds could become exit ramps for uneven growth stories rather than engines of long-term value [3].
Inside the debate, Peyush Bansal—famed from Shark Tank India—is cited defending the valuation. Critics retort that retail investors are being treated as 'dumb money,' a dynamic that would tilt due-diligence toward listing gains rather than fundamentals [4].
The verdict will hinge on long-term growth vs listing hype as Lenskart prepares to list.
References
From valuing startups on Shark Tank to "I don’t get valuations"
Lenskart IPO; discuss subscribe vs avoid, listing potential, fundamentals and growth, 70k mcap
View sourceValuation defies logic - Lenskart IPO raises serious questions for mutual fund manager’s discipline
Lenskart IPO overpriced; funds' discipline questioned; comparisons with Zomato/Eternal; debate over valuations and anchor-investor practices retail investors' exposure discussed too
View sourcePeyush Bansal regarding Lenskart IPO Valuation
Discusses Lenskart IPO valuation; criticizes overvaluation; mentions mutual funds; retail investor concerns; market bias; regulatory watch and AMCs investment hype.
View source